Skip to main content
SpringerLink
Log in

Use of Monoclonal Antibodies in Corneal Transplantation

  • Disease Treatment Review
  • Published:
Clinical Immunotherapeutics Aims and scope Submit manuscript

Summary

Murine monoclonal antibodies are used to abrogate immunological rejection of vascularised organ grafts in humans. The most widely-used antibody, muromonab CD3 (OKT3), has specificity for the human peripheral T cell antigen CD3. Systemic administration of muromonab CD3 in essential organ transplantation is associated with 2 major types of complications: infections and the so-called cytokine release syndrome. In addition, most recipients produce antibodies to the heterologous murine immunoglobulin. Muromonab CD3 has also been implicated in precipitating some ocular complications. Some of these adverse effects are likely to be attendant on the administration of any immunosuppressive murine monoclonal antibody, irrespective of specificity.

The use of monoclonal antibodies in corneal transplantation has thus far been limited, and has been restricted primarily to studies in experimental animals. Systemic administration of monoclonal antibodies with specificity for the T cell subset determinant CD4 has already been shown to prolong orthotopic corneal allograft and heterotopic corneal xenograft survival in small rodents. Further, the intracameral injection of anti-T cell monoclonal antibodies into the anterior chamber of the eye has been shown to reverse acute corneal graft rejection in humans, while antibodies with specificity for T cells and myeloid cells were similarly effective in a rabbit model. These studies clearly demonstrate that monoclonal antibodies can be used to both prevent and reverse corneal graft rejection.

The challenges are now 3-fold. First, the most appropriate specificity and route of administration of monoclonal antibodies for the immunosuppression of corneal grafts need to be determined. Secondly, it will be necessary to establish that these reagents can be given safely in the clinical setting without causing unacceptable adverse effects. Finally, it must be confirmed that monoclonal antibodies will prove to be useful adjuncts (or better alternatives) to existing regimens of immunosuppression for corneal transplantation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 475–81

    Article  Google Scholar 

  2. Williams KA, Muehlberg SM, Wing SJ, et al. The Australian Corneal Graft Registry, 1990-1992 report. Aust NZ J Ophthalmol 1993; 21(Suppl.): 1–48

    Google Scholar 

  3. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495–7

    Article  PubMed  Google Scholar 

  4. Cosimi AB, Burton RC, Colvin RB, et al. Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation 1981; 32: 535–9

    Article  PubMed  CAS  Google Scholar 

  5. Ortho Multicenter Transplant Study Group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 1985; 313: 337–42

    Google Scholar 

  6. Cosimi AB, Cho SI, Delmonico FL, et al. A randomized clinical trial comparing OKT3 and steroids for treatment of hepatic allograft rejection. Transplantation 1987; 43: 91–5

    Article  PubMed  CAS  Google Scholar 

  7. Colonna JO, Goldstein LI, Brems JJ, et al. A prospective study on the use of monoclonal anti-T3-cell antibody (OKT3) to treat steroid-resistant liver transplant rejection. Arch Surg 1987; 122: 1120–3

    Article  PubMed  Google Scholar 

  8. Gilbert EM, Dewitt CW, Eiswirth CC, et al. Treatment of refractory cardiac allograft rejection with OKT3 monoclonal antibody. Am J Med 1987; 82: 202–6

    Article  PubMed  CAS  Google Scholar 

  9. Cecka JM, Gjertson D, Terasaki PI. Do prophylactic antilymphocyte globulins (ALG and OKT3) improve renal transplant survival in recipient and donor high-risk groups? Transplant Proc 1993; 25: 548–9

    PubMed  CAS  Google Scholar 

  10. Millis JM, McDiarmid SV, Hiatt JR, et al. Randomized prospective trial of OKT3 for early prophylaxis of rejection after liver transplantation. Transplantation 1989; 47: 82–8

    Article  PubMed  CAS  Google Scholar 

  11. Gilbert EM, Eiswirth CC, Renlund DG, et al. Use of Orthoclone OKT3 monoclonal antibody in cardiac transplantation: early experience with rejection prophylaxis and treatment of refractory rejection. Transplant Proc 1987; 19(1 Suppl.): 45–53

    PubMed  CAS  Google Scholar 

  12. Oh CS, Stratta RJ, Fox BC, et al. Increased infections associated with the use of OKT3 for treatment of steroid-resistant rejection in renal transplantation. Transplantation 1988; 45: 68–73

    Article  PubMed  CAS  Google Scholar 

  13. Jeyarajah DR, Thistlethwaite JR. General aspects of cytokinerelease syndrome: timing and incidence of symptoms. Transplant Proc 1993; 25 (1 Suppl.): 16–20

    Google Scholar 

  14. Abramowicz D, Schandene L, Goldman M, et al. Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney graft recipients. Transplantation 1989; 47: 606–8

    Article  PubMed  CAS  Google Scholar 

  15. Chatenoud L, Ferran C, Legendre C, et al. In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids. Transplantation 1990; 49: 697–702

    Article  PubMed  CAS  Google Scholar 

  16. Chatenoud L. OKT3-induced cytokine-release syndrome: preventive effect of anti-tumor necrosis factor monoclonal antibody. Transplant Proc 1993; 25 (1 Suppl.): 47–51

    Google Scholar 

  17. Jaffers GJ, Fuller TC, Cosimi AB, et al. Monoclonal antibody therapy: anti-idiotypic and non-anti-idiotypic antibodies to OKT3 arising despite intense immunosuppression. Transplantation 1986; 41: 572–8

    Article  PubMed  CAS  Google Scholar 

  18. Chatenoud L, Baudrihaye MF, Chkoff N, et al. Restriction of the human in vivo immune response against the mouse monoclonal antibody OKT3. J Immunol 1986; 137: 830–8

    PubMed  CAS  Google Scholar 

  19. Chatenoud L. Humoral immune response against OKT3. Transplant Proc 1993; 25(1 Suppl.): 68–73

    PubMed  CAS  Google Scholar 

  20. Chatenoud L, Bach J-F. Therapeutic monoclonal antibodies in transplantation. Transplant Proc 1993; 25: 473–4

    PubMed  CAS  Google Scholar 

  21. McCarthy JM, Sullivan K, Keown PA, et al. Diffuse anterior scleritis during monoclonal antibody therapy for renal transplant rejection. Can J Ophthalmol 1992; 27: 22–4

    PubMed  CAS  Google Scholar 

  22. Dukar O, Barr CC. Visual loss complicating OKT3 monoclonal antibody therapy. Am J Ophthalmol 1993; 115: 781–5

    PubMed  CAS  Google Scholar 

  23. Shihab FS, Barry JM, Norman DJ. Encephalopathy following the use of OKT3 in renal allograft rejection. Transplant Proc 1993; 25(1 Suppl.): 31–4

    PubMed  CAS  Google Scholar 

  24. Norman DJ, Chatenoud L, Cohen D, et al. Consensus statement regarding OKT3-induced cytokine-release syndrome and human antimouse antibodies. Transplant Proc 1993; 25(1 Suppl.): 89–92

    PubMed  CAS  Google Scholar 

  25. Dantal J, Soulillou J-P. Use of monoclonal antibodies in human transplantation. Curr Opin Immunol 1991; 3: 740–7

    Article  PubMed  CAS  Google Scholar 

  26. Ito T, Miyasaka M, Nozawa M. Monoclonal antibodies to adhesion molecules: therapeutic use in transplant rejection. Clin Immunother 1994; 1: 460–8

    Article  Google Scholar 

  27. Norman DJ, Bennett WM, Cobanoglu A, et al. Use of OKT4A (a murine monoclonal anti-CD4 antibody) in human organ transplantation: initial clinical experience. Transplant Proc 1993; 25: 802–3

    PubMed  CAS  Google Scholar 

  28. Reiter CH, Meiser BM, Uberfuhr P, et al. Selection and chimerization of a monoclonal CD4 antibody for heart transplantation. Transplant Proc 1993; 25: 788–9

    PubMed  CAS  Google Scholar 

  29. Le Mauff B, Hourmant M, Rougier J-P, et al. Effect of anti-LFA1 (CD 11 a) monoclonal antibodies in acute rejection in human kidney transplantation. Transplantation 1991; 52: 291–6

    Article  PubMed  Google Scholar 

  30. Haug CE, Colvin RB, Delmonoco FL, et al. A phase I trial of immunosuppression with anti-ICAM-1 (CD54) mAb in renal allograft recipients. Transplantation 1993; 55: 766–73

    Article  PubMed  CAS  Google Scholar 

  31. Soulillou J-P, Cartovarich D, Le Mauff B, et al. Randomized trial of an anti-interleukin 2 receptor monoclonal antibody (33B3.1) versus rabbit antithymocyte globulin (ATG) in prophylaxis of early rejection in human renal transplantation. N Engl J Med 1990; 322: 1175–82

    Article  PubMed  CAS  Google Scholar 

  32. Kriaa F, Hiesse C, Alard P, et al. Prophylactic use of the anti-IL-2 receptor monoclonal antibody LO-Tact-1 in cadaveric renal transplantation: results of a randomized study. Transplant Proc 1993; 25: 817–9

    PubMed  CAS  Google Scholar 

  33. Herbert J, Roser B. Strategies of monoclonal antibody therapy that induce permanent tolerance of organ transplants. Transplantation 1988; 46(Suppl.): 128–34

    Article  Google Scholar 

  34. Sablinski T, Hancock WH, Tilney NL, et al. CD4 monoclonal antibodies in organ transplantation - a review of progress. Transplantation 1991; 52: 579–89

    Article  PubMed  CAS  Google Scholar 

  35. Waldmann H. Immunosuppression with monoclonal antibodies: some speculations about tolerance in the context of tissue grafting. Transplant Proc 1988; 20 (8 Suppl.): 46–52

    Google Scholar 

  36. Waltman SR, Faulkner WM, Burde RM. Modification of the ocular immune response. I. Use of antilymphocytic serum to prevent immune rejection of penetrating corneal homografts. Invest Ophthalmol 1972; 8: 196–200

    Google Scholar 

  37. Polack FM, Townsend WM, Waltman S. Antilymphocyte serum and corneal graft rejection. Am J Ophthalmol 1972; 73: 52–5

    PubMed  CAS  Google Scholar 

  38. Smolin G. Corneal homograft reaction following subconjunctival antilymphocyte serum. Am J Ophthalmol 1969; 67: 137–9

    PubMed  CAS  Google Scholar 

  39. Ayliffe W, Alam Y, Bell EB, et al. Prolongation of rat corneal graft survival by treatment with anti-CD4 monoclonal antibody. Br J Ophthalmol 1992; 76: 602–6

    Article  PubMed  CAS  Google Scholar 

  40. He YG, Ross J, Niederkorn JY. Promotion of murine orthotopic corneal allograft survival by systemic administration of anti-CD4 monoclonal antibody. Invest Ophthalmol Vis Sci 1991; 32: 2723–8

    PubMed  CAS  Google Scholar 

  41. Duguid IGM, Koulmanda M, Mandel TE. Prolongation of heterotopic human corneal graft survival in mice treated with an anti-CD4 monoclonal antibody. Transplant Proc 1990; 22: 2107–8

    PubMed  CAS  Google Scholar 

  42. Guymer RH, Mandel TE. Monoclonal antibody to ICAM-1 prolongs murine heterotopic corneal allograft survival. Aust NZ J Ophthalmol 1991; 19: 141–4

    Article  CAS  Google Scholar 

  43. Shirao E, Deschênes J, Char DH. Corneal allograft rejection in rabbits. Curr Eye Res 1986; 5: 817–22

    Article  PubMed  CAS  Google Scholar 

  44. Williams KA, Standfield SD, Wing SJ, et al. Patterns of corneal graft rejection in the rabbit and reversal of rejection with monoclonal antibodies. Transplantation 1992; 54: 38–43

    Article  PubMed  CAS  Google Scholar 

  45. Williams KA, Coster DJ. Local injection of monoclonal antibodies into the anterior chamber of rabbits with corneal graft rejection. In: Usui M, Ohno S, Aoki K, editors. Ocular immunology today. Amsterdam: Elsevier, 1990: 107–10

    Google Scholar 

  46. Ippoliti G, Fronterrè A. Use of locally injected anti-T monoclonal antibodies in the treatment of acute corneal graft rejection. Transplant Proc 1987; 19: 2579–80

    PubMed  CAS  Google Scholar 

  47. Ippoliti G, Fronterrè A. Usefulness of CD3 or CD6 anti-T monoclonal antibodies in the treatment of acute corneal graft rejection. Transplant Proc 1989; 21: 3133–4

    PubMed  CAS  Google Scholar 

  48. Council on Scientific Affairs. Report of the organ transplant panel: corneal transplantation. JAMA 1988; 259: 719–22

    Google Scholar 

Download references

Acknowledgements

This work was supported by the Ophthalmic Research Institute of Australia and the National Health and Medical Research Council. We thank E.W. Johnstone for the artwork.

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Flinders University of South Australia, Flinders Medical Centre, Bedford Park, South Australia, 5042, Adelaide, Australia

    Keryn A. Williams & Douglas J. Coster

Authors
  1. Keryn A. Williams
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Douglas J. Coster
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Williams, K.A., Coster, D.J. Use of Monoclonal Antibodies in Corneal Transplantation. Clin Immunother 2, 32–41 (1994). https://doi.org/10.1007/BF03258520

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03258520

Keywords

Search

Navigation